SteadyMed Provides Corporate Update And Reports Fourth Quarter And Full Year 2016 Financial Results

SAN RAMON, Calif., March 29, 2017 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug product candidates to treat orphan and high-value diseases with unmet parenteral delivery needs, today provided a corporate update and announced its financial results for the fourth quarter and full year ended December 31, 2016.

Back to news